JPWO2019219312A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019219312A5 JPWO2019219312A5 JP2020556748A JP2020556748A JPWO2019219312A5 JP WO2019219312 A5 JPWO2019219312 A5 JP WO2019219312A5 JP 2020556748 A JP2020556748 A JP 2020556748A JP 2020556748 A JP2020556748 A JP 2020556748A JP WO2019219312 A5 JPWO2019219312 A5 JP WO2019219312A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cell
- cancer
- nucleic acid
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 40
- 206010028980 Neoplasm Diseases 0.000 claims 18
- 239000011230 binding agent Substances 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000013604 expression vector Substances 0.000 claims 9
- 108020001507 fusion proteins Proteins 0.000 claims 9
- 102000037865 fusion proteins Human genes 0.000 claims 9
- 239000002671 adjuvant Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 108091008874 T cell receptors Proteins 0.000 claims 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 102000015696 Interleukins Human genes 0.000 claims 3
- 108010063738 Interleukins Proteins 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 239000003139 biocide Substances 0.000 claims 3
- 230000022534 cell killing Effects 0.000 claims 3
- 238000002659 cell therapy Methods 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 230000005847 immunogenicity Effects 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000012931 lyophilized formulation Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000010186 staining Methods 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 108010028930 invariant chain Proteins 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229940038309 personalized vaccine Drugs 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 238000012070 whole genome sequencing analysis Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024184854A JP2025016534A (ja) | 2018-05-16 | 2024-10-21 | がんに対する免疫療法で使用するためのペプチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862672411P | 2018-05-16 | 2018-05-16 | |
| DE102018111819.8 | 2018-05-16 | ||
| DE102018111819 | 2018-05-16 | ||
| US62/672,411 | 2018-05-16 | ||
| PCT/EP2019/059522 WO2019219312A1 (en) | 2018-05-16 | 2019-04-12 | Peptides for use in immunotherapy against cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024184854A Division JP2025016534A (ja) | 2018-05-16 | 2024-10-21 | がんに対する免疫療法で使用するためのペプチド |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021522779A JP2021522779A (ja) | 2021-09-02 |
| JPWO2019219312A5 true JPWO2019219312A5 (https=) | 2022-04-20 |
| JP2021522779A5 JP2021522779A5 (https=) | 2022-04-20 |
| JP7578491B2 JP7578491B2 (ja) | 2024-11-06 |
Family
ID=66182582
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556748A Active JP7578491B2 (ja) | 2018-05-16 | 2019-04-12 | がんに対する免疫療法で使用するためのペプチド |
| JP2024184854A Pending JP2025016534A (ja) | 2018-05-16 | 2024-10-21 | がんに対する免疫療法で使用するためのペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024184854A Pending JP2025016534A (ja) | 2018-05-16 | 2024-10-21 | がんに対する免疫療法で使用するためのペプチド |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US11214604B2 (https=) |
| EP (1) | EP3793592A1 (https=) |
| JP (2) | JP7578491B2 (https=) |
| KR (1) | KR20210010459A (https=) |
| CN (2) | CN112135629A (https=) |
| AU (1) | AU2019270985A1 (https=) |
| BR (1) | BR112020021096A2 (https=) |
| CA (1) | CA3097591A1 (https=) |
| CL (1) | CL2020002935A1 (https=) |
| CO (1) | CO2020013652A2 (https=) |
| CR (1) | CR20200551A (https=) |
| MA (1) | MA52614A (https=) |
| MX (1) | MX2020012255A (https=) |
| PE (1) | PE20210126A1 (https=) |
| PH (1) | PH12020551958A1 (https=) |
| SG (2) | SG10202110291WA (https=) |
| TW (1) | TW202016131A (https=) |
| WO (1) | WO2019219312A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201515321D0 (en) * | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| TW202016131A (zh) * | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| CN115785254A (zh) * | 2019-12-13 | 2023-03-14 | 南京大户生物科技有限公司 | 原发性肝癌相关抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用 |
| CN116334031A (zh) * | 2022-07-21 | 2023-06-27 | 中国人民解放军陆军军医大学 | 三个多肽及其在制备ⅰ型糖尿病免疫防治疫苗或药物中的应用 |
| CN115109117B (zh) * | 2022-08-12 | 2024-08-16 | 齐鲁工业大学 | 一种多管藻藻红蛋白血管紧张素转化酶抑制肽及其制备方法与应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IL59007A (en) | 1978-12-22 | 1983-11-30 | Biogen Nv | Recombinant dna molecules coding for polypeptides displaying hepatitis b virus antigenicity,method of their production and compositions containing the same |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| AU6852594A (en) | 1993-06-03 | 1995-01-03 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| ES2203782T3 (es) | 1996-01-17 | 2004-04-16 | Imperial College Innovations Limited | Inmunoterapia que utiliza linfocitos t citotoxicos (ctl). |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6635742B1 (en) * | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| DE60142475D1 (de) | 2000-03-27 | 2010-08-12 | Technion Res And Dev Of Founda | Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| EP2322228B1 (en) | 2000-06-05 | 2018-01-10 | Altor BioScience Corporation | T cell receptor fusion proteins and conjugates and methods of use thereof |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| DE60327795D1 (de) | 2002-11-09 | 2009-07-09 | Immunocore Ltd | T zell rezeptor "display" |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| ES2341802T3 (es) | 2005-09-05 | 2010-06-28 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii. |
| CA2625403A1 (en) | 2005-10-17 | 2007-04-26 | Institute For System Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| EP2520935A3 (en) * | 2006-08-09 | 2013-02-13 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| EP2300040A4 (en) * | 2008-05-01 | 2012-06-27 | Beth Israel Hospital | METHOD AND COMPOSITIONS FOR IMMUNOTHERAPY IN PROSTATE CANCER |
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| US20140170168A1 (en) | 2010-10-26 | 2014-06-19 | Yoram Reiter | Antibodies which bind soluble t-cell receptor ligands |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| US12540318B2 (en) | 2012-11-08 | 2026-02-03 | Roche Diagnostics Operations, Inc. | Nucleic acids encoding chimeric polypeptides for library screening |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| TWI775117B (zh) * | 2013-08-05 | 2022-08-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二） |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201507030D0 (en) * | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201511191D0 (en) * | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| GB201511546D0 (en) * | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201515321D0 (en) * | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201520563D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| EA201892159A1 (ru) | 2016-04-06 | 2019-03-29 | Имматикс Байотекнолоджиз Гмбх | Новые пептиды и комбинации пептидов для применения в иммунотерапии омл и других видов рака |
| US11261223B2 (en) | 2016-05-11 | 2022-03-01 | The University Of Chicago | Methods of treating cancers with CT45 targeted therapies |
| MA47367B1 (fr) * | 2017-01-27 | 2023-06-28 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
| US10800823B2 (en) * | 2017-07-07 | 2020-10-13 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
| US20210061914A1 (en) | 2017-12-28 | 2021-03-04 | Gritstone Oncology, Inc. | Antigen-Binding Proteins Targeting Shared Antigens |
| TW202016131A (zh) * | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| TW202019955A (zh) * | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| GB201814362D0 (en) * | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Composition and process for preparing vaccine |
-
2019
- 2019-03-27 TW TW108110593A patent/TW202016131A/zh unknown
- 2019-04-12 AU AU2019270985A patent/AU2019270985A1/en not_active Abandoned
- 2019-04-12 BR BR112020021096-0A patent/BR112020021096A2/pt unknown
- 2019-04-12 CR CR20200551A patent/CR20200551A/es unknown
- 2019-04-12 SG SG10202110291W patent/SG10202110291WA/en unknown
- 2019-04-12 JP JP2020556748A patent/JP7578491B2/ja active Active
- 2019-04-12 MX MX2020012255A patent/MX2020012255A/es unknown
- 2019-04-12 SG SG11202009442YA patent/SG11202009442YA/en unknown
- 2019-04-12 CN CN201980032539.6A patent/CN112135629A/zh active Pending
- 2019-04-12 PE PE2020001848A patent/PE20210126A1/es unknown
- 2019-04-12 CA CA3097591A patent/CA3097591A1/en active Pending
- 2019-04-12 MA MA052614A patent/MA52614A/fr unknown
- 2019-04-12 KR KR1020207032827A patent/KR20210010459A/ko not_active Ceased
- 2019-04-12 WO PCT/EP2019/059522 patent/WO2019219312A1/en not_active Ceased
- 2019-04-12 CN CN202011499239.XA patent/CN113150115A/zh active Pending
- 2019-04-12 EP EP19717884.1A patent/EP3793592A1/en not_active Withdrawn
- 2019-05-15 US US16/413,439 patent/US11214604B2/en not_active Expired - Fee Related
-
2020
- 2020-10-29 CO CONC2020/0013652A patent/CO2020013652A2/es unknown
- 2020-11-12 CL CL2020002935A patent/CL2020002935A1/es unknown
- 2020-11-16 PH PH12020551958A patent/PH12020551958A1/en unknown
-
2021
- 2021-06-25 US US17/358,703 patent/US11208449B2/en not_active Expired - Fee Related
- 2021-07-02 US US17/366,837 patent/US11685769B2/en active Active
-
2023
- 2023-01-30 US US18/161,423 patent/US12060400B2/en active Active
-
2024
- 2024-07-01 US US18/760,718 patent/US20240425558A1/en active Pending
- 2024-10-21 JP JP2024184854A patent/JP2025016534A/ja active Pending